BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
America Great Health AAGH
14 fiscal years on record · USD · FY2024 reported · SEC filings only
$-719,119
Growth
USD 391,743.00
Revenue, FY2024 · full 14-year series below
Revenue $M
Net income $M
FY2024 · Revenue 0.4 · Net income -0.7
Compound annual growth
Revenue compounded at +134.9% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−184 cents
lost on every revenue dollar
Operating margin
Net margin
FY2024 · Operating -97.8% · Net -184.1%
ROE
Not applicable: equity was negative in this period, so return on equity has no meaning.
Gross margin86.6%
Operating margin-97.8%
Net margin-184.1%
Return on assets-230.7%
EBITDAUSD -368,147.00
The 14-year record
14 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · | · | · |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · | · | · | · | · | · | · |
| Income tax $B | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · | · | · | · | · | · |
| EPS, diluted $ | 0.00 | 0.00 | 0.00 | · | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Shares out B | 21.15 | 21.14 | 21.11 | 21.09 | 21.07 | 20.24 | 20.24 | 20.24 | 20.24 | 20.06 | 19.98 | 19.98 | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 53 reconciliationsAUDITED
Reconciled in 15 of 19 fiscal years. 42 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inCalifornia
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2011